A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications CNS cancer; Ewing's sarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 30 Dec 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Nov 2011 Planned end date (November 2011) added as reported by ClinicalTrials.gov.